A China Tech Fund Opens a Biotech Position — Here's What That Actually Signals

1 hour ago 2

Seena Hassouna, The Motley Fool

Sun, May 17, 2026 astatine 2:56 PM CDT 4 min read

First Beijing Investment Ltd disclosed a caller presumption successful Legend Biotech (NASDAQ:LEGN), acquiring 2,296,335 shares successful the archetypal quarter, with the estimated commercialized valued astatine $43.78 cardinal based connected mean quarterly pricing, according to a May 13, 2026, SEC filing.

Legend Biotech develops compartment therapies for cancer, with a pipeline spanning hematologic malignancies and coagulated tumors.

Initiated caller stake: 2,296,335 shares; estimated commercialized worth $43.78 cardinal (based connected quarterly mean price)
Quarter-end presumption worth astatine $41.54 million, representing a nett valuation alteration that includes terms movements
Trade represented a 1.89% summation successful 13F reportable assets nether management
Post-trade: 2,296,335 shares held, valued astatine $41.54 million
Position accounts for 1.79% of 13F AUM, which places it extracurricular the fund's apical 5 holdings

What happened

According to an SEC filing dated May 13, 2026, First Beijing Investment Ltd established a caller involvement successful Legend Biotech, purchasing 2,296,335 shares. The estimated transaction worth was $43.78 million, calculated utilizing the mean closing terms for the archetypal quarter. The quarter-end worth of this presumption stood astatine $41.54 million, reflecting some acquisition enactment and stock terms question during the period.

What other to cognize

New position: involvement represents 1.79% of 13F reportable assets nether absorption arsenic of March 31, 2026
Top holdings aft the filing:
- NASDAQ: PDD: $832.68 cardinal (35.9% of AUM)
- NYSE: YMM: $747.01 cardinal (32.2% of AUM)
- NYSE: EDU: $509.40 cardinal (22.0% of AUM)
- NYSE: RLX: $132.29 cardinal (5.7% of AUM)
- NASDAQ: KSPI: $32.17 cardinal (1.4% of AUM)
As of May 15, 2026, Legend Biotech shares were priced astatine $27.55, down 0.5% implicit the anterior year, underperforming the S&P 500 by 25.7 percent points

Company Overview

Metric

Value

Price (as of marketplace adjacent 2026-05-15)	$27.55
Market Capitalization	$5.08 billion
Revenue (TTM)	$1.14 billion
Net Income (TTM)	($250.98 million)

Company Snapshot

Legend Biotech develops and commercializes caller compartment therapies, including its pb CAR-T merchandise campaigner for aggregate myeloma and a pipeline targeting assorted hematologic malignancies and coagulated tumors.
The institution generates gross chiefly done the improvement and licensing of its compartment therapy portfolio, leveraging strategical collaborations specified arsenic its statement with Janssen Biotech for ciltacabtagene autoleucel.
Legend Biotech targets oncology patients, healthcare providers, and pharmaceutical partners successful the United States, China, and planetary markets.

Legend Biotech Corporation is simply a clinical-stage biopharmaceutical institution focused connected advancing innovative compartment therapies for crab and related diseases. The institution leverages proprietary CAR-T technologies and strategical partnerships to code precocious unmet aesculapian needs successful oncology. With a increasing portfolio and planetary presence, Legend Biotech aims to found a competitory presumption successful the planetary biotechnology sector.

Read Entire Article